HomeCompareSFFLY vs PFE

SFFLY vs PFE: Dividend Comparison 2026

SFFLY yields 3.44% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $29.2K in total portfolio value· pulled ahead in Year 9
10 years
SFFLY
SFFLY
● Live price
3.44%
Share price
$8.28
Annual div
$0.28
5Y div CAGR
-46.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.4K
Annual income
$0.70
Full SFFLY calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — SFFLY vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSFFLYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SFFLY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SFFLY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SFFLY
Annual income on $10K today (after 15% tax)
$292.00/yr
After 10yr DRIP, annual income (after tax)
$0.60/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $22,319.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SFFLY + PFE for your $10,000?

SFFLY: 50%PFE: 50%
100% PFE50/50100% SFFLY
Portfolio after 10yr
$35.0K
Annual income
$13,129.71/yr
Blended yield
37.56%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

SFFLY
No analyst data
Altman Z
1.5
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SFFLY buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSFFLYPFE
Forward yield3.44%6.13%
Annual dividend / share$0.28$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-46.4%13.2%
Portfolio after 10y$20.4K$49.6K
Annual income after 10y$0.70$26,258.71
Total dividends collected$401.00$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SFFLY vs PFE ($10,000, DRIP)

YearSFFLY PortfolioSFFLY Income/yrPFE PortfolioPFE Income/yrGap
1$10,884$184.13$9,153$693.39+$1.7KSFFLY
2$11,746$100.39$8,593$849.25+$3.2KSFFLY
3$12,623$54.27$8,336$1,066.78+$4.3KSFFLY
4$13,536$29.22$8,437$1,384.80+$5.1KSFFLY
5$14,499$15.69$9,013$1,875.40+$5.5KSFFLY
6$15,522$8.42$10,306$2,680.72+$5.2KSFFLY
7$16,613$4.52$12,820$4,101.38+$3.8KSFFLY
8$17,779$2.42$17,673$6,826.70+$106.00SFFLY
9← crossover$19,025$1.30$27,543$12,591.86$8.5KPFE
10$20,357$0.70$49,560$26,258.71$29.2KPFE

SFFLY vs PFE: Complete Analysis 2026

SFFLYStock

Schaeffler AG, together with its subsidiaries, manufactures and sells precision components and systems for automotive and industrial applications in Europe, the Americas, China, and the Asia Pacific. The company's Automotive OEM division offers engine systems, including rolling bearing solutions, belt and chain drive products, valve train components, and systems for variable valve trains; and transmission systems, such as torsion and vibration dampers, clutches and double clutch systems, torque converters, CVT components, lightweight differentials, bearing solutions, and synchronizing and gearshift components. This division also provides chassis systems comprising wheel bearings, bearing solutions, steering components, electromechanical actuators for roll stabilizers, and power-assisted steering systems; and hybrid and electrical drive systems that include hybrid modules, electrical axle drives, and electrical wheel hub drives. Its Automotive Aftermarket division offers repair solutions for passenger cars, light commercial vehicles, heavy commercial vehicles, and tractors, as well as supporting services. The company's Industrial division provides components and systems. This division serves customers in the mobility, energy and raw materials, production machinery, aerospace, and industrial distribution. The company has a strategic partnership with Fraunhofer-Gesellschaft. The company was formerly known as INA Beteiligungsgesellschaft mit beschränkter Haftung and changed its name to Schaeffler AG in October 2014. The company was founded in 1946 and is headquartered in Herzogenaurach, Germany. Schaeffler AG is a subsidiary of IHO Verwaltungs GmbH.

Full SFFLY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this SFFLY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SFFLY vs SCHDSFFLY vs JEPISFFLY vs OSFFLY vs KOSFFLY vs MAINSFFLY vs JNJSFFLY vs MRKSFFLY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.